## 23andMe Study: Genetic Markers May Predict Weight Loss, Side Effects on GLP-1 Drugs
A new study from 23andMe suggests a person's genetics could be a key factor in determining how well they respond to blockbuster GLP-1 weight-loss drugs like Wegovy and Zepbound. Published in *Nature*, the research identifies specific changes in two genes that appear to help predict not only whether a patient will lose substantial weight on the medications, but also their likelihood of experiencing common side effects like nausea and vomiting. This finding points to a potential future where genetic screening could personalize obesity treatment, moving beyond the current trial-and-error approach.

The research, led by 23andMe's Adam Auton, represents a significant step in connecting genetic data to drug response. While the study offers a compelling 'proof of concept,' as Auton stated, its immediate clinical impact is debated. Outside researchers expressed intrigue but also skepticism, questioning whether these genetic predictors are strong enough to alter real-world patient care decisions at this stage. Despite the scientific debate, 23andMe is moving forward commercially: customers on its premium Total Health platform will soon have access to their own data related to these genetic markers and the associated predictions for GLP-1 drug use.

This development places 23andMe at the intersection of direct-to-consumer genetics, big data research, and the booming market for obesity therapeutics. It signals a push towards more personalized medicine but also raises questions about the readiness of such genetic insights for clinical application. The move to provide this data directly to consumers could create pressure on healthcare providers to interpret and act on genetic risk information that is still emerging from academic research.
---
- **Source**: STAT News
- **Sector**: The Lab
- **Tags**: genetics, obesity, personalized medicine, pharmacogenomics, GLP-1
- **Credibility**: unverified
- **Published**: 2026-04-08 22:26:49
- **ID**: 55714
- **URL**: https://whisperx.ai/en/intel/55714